2751-09-9CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=OLQCLVBQBTUVCEQ-GSELTXNRSA-N安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
使用Troleandomycin, is a macrolide antibiotic, sold in Italy and Turkey. It is a derivative of Oleandomycin (O517500), and acts as a CYP3A4 inhibitor, which may cause drug interactions .
一般的な説明Triacetyloleandomycin was synthesized by Pfizer Research Laboratories in 1958. It shows a higher and longer-lasting serum level than oleandomycin when administered orally. Triacetyloleandomycin behaves as oleandomycin in vivo, following its hydrolysis by intestinal esterase. However, considerable amounts of the intermediates, the monoacetates and diacetates, are detected in the serum and urine. Prolonged use of triacetyloleandomycin causes damage to the liver as does erythromycin estolate.
現在のフィルター条件では反応記録がありません。
読み込み中…
2751-09-9CHEMBL1200719定義ChEBI: A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.